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Abstract 
Antimicrobial peptides (AMPs) are extensive group of molecules that produced by variety tissues of 
invertebrate, plants, and animal species which play an important role in their immunity response. AMPs have 
different classifications such as; biosynthetic machines, biological sources, biological functions, molecular 
properties, covalent bonding patterns, three dimensional structures, and molecular targets.  
These molecules have multidimensional properties including antimicrobial activity, antiviral activity, 
antifungal activity, anti-parasite activity, biofilm control, antitumor activity, mitogens activity and linking 
innate to adaptive immunity that making them promising agents for therapeutic drugs. In spite of this advantage 
of AMPs, their clinical developments have some limitation for commercial development. But some of AMPs 
are under clinical trials for the therapeutic purpose such as diabetic foot ulcers, different bacterial infections and 
tissue damage. In this review, we emphasized on the source, structure, multidimensional properties, limitation 
and therapeutic applications of various antimicrobial peptides. 
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Natural antibiotics that produce by a variety of 
tissues and cell types organisms against pathogenic 
microorganisms are considered as antimicrobial 
peptides1,2. Nowadays antibiotic resistance has 
become a major public health problem around the 
world and so other antimicrobial agents against 
organisms should be used3. Antimicrobial peptides 
(AMPs) play an important role in innate immune 
responses against infections in different organisms4. 
The role of antimicrobial peptides in innate immunity 
was demonstrated by Metchnikoff5. For example 
some AMPs that produced by insects can protect them 
from variety of pathogens such as bacteria, viruses or 
fungi. α-defensins that isolated from mammalian 
leukocytes showed that this line of defense is not 
exclusively be found in the organisms that lack an 
acquired immune system6,7. Because of their 
potentially usefulness in clinical applications, many 
researches are undergoing for development of peptide 
antibiotics as a new class of anti-infective drugs8. 
AMPs have general structural features that are shared 
by a majority of AMPs such as length, net charge and 
hydrophobicity. They are commonly composed of less 
than 100 amino acid residues (generally between 12 to 
NBM 70   Novelty in Biomedicine 2016, 2, 70-6 
Antimicrobial Peptides (AMPs)                                                                                                 Sadredinamin et al. 
50 amino acids) and show different net charges from 
0 to +7 and hydrophobic percentages between 31–
70%7,9. Antimicrobial peptides can be produced by a 
variety of sources including insects, amphibians, 
echinoderms, crustaceans, plants, mammals, bacteria, 
fungi, and fishes. More than 2453 AMPs from 
various organisms have been identified in the 
antimicrobial peptide database including 244 AMPs 
from bacteria (i.e., bacteriocins), 2 from archaea, 7 
from protists, 13 from fungi, 311 from plants, and 
1835 from animals 
(http://aps.unmc.edu/AP/main.php). 
Discovery of AMPs 
The discovery of AMPs dates back to 1922, when 
Alexander Fleming discovered human lysozyme in 
saliva. In 1939, another AMP, gramicidin, was 
discovered by Hotchkiss and Dubos7,10. The 
discovery of antimicrobial peptides in later years has 
continued until today. For example some of 
important AMPs which have been discovered until 
now include Plant Kalata B1 in 1973, cecropins that 
produced by insects in 1980, magainin from frog in 
1987, defensins that produced by human cells and 
mammalian cells in 19857. 
Classification of AMPs 
There are various classifications of antimicrobial 
peptides based on: The biosynthetic machines, 
biological sources, biological functions, molecular 
properties, covalent bonding patterns, 3 dimensional 
structures, molecular targets. 
According to the biosynthetic machines natural 
peptides can be classified as gene coded and non-
gene coded. Based on biological sources AMPs can 
classified as bacterial AMPs (bacteriocins), plant 
AMPs, and animal AMPs that animal AMPs are 
further classified into insect AMPs, amphibian 
AMPs, fish AMPs, reptile AMPs, and mammal 
AMPs. According to the biological functions AMPs 
can act as antibacterial, antifungal, antiviral, 
antiparasite, anticancer, anti- protest, insecticidal, 
spermicidal, chemotactic, antioxidant and protease 
inhibitors. 
In the absence of three-dimensional (3D) structural 
information, AMPs can be classified based on 
peptide properties such as charge (cationic, neutral, 
and anionic peptides), hydrophobicity (hydrophobic, 
amphipathic, and hydrophilic peptides), and length 
(ultra-small (2-10 aa), small (10-24 aa), medium (25-
50 aa), and large (50-100 aa). 
One of the universal classification systems (UC) 
according to the covalent bonding patterns leads to 
four classes of antimicrobial peptides, UCLL: linear 
one-chain peptides (e.g. LL-37 and magainins) or two 
linear peptides not connected via a covalent bond, 
UCSS: sidechain-linked peptides (e.g. disulfide-
containing defensins or ether bond-containing 
lantibiotics). A sidechain-sidechain connection can 
occur within a single peptide chain or between two 
different peptide chains, UCSB: polypeptide chains 
with a sidechain to backbone connection, UCBB: 
circular polypeptides with a peptide bond between the 
N- and C-termini that found in bacteria (like AS-48), 
plants (cyclotides), and animals (theta-defensins). 
According to the 3dimentional structures the types of 
secondary structures are used for the classification of 
AMPs into four families: α- helix, β- sheet, extended 
and loop. 
AMPs can be broadly classified into two families 
based on the molecular targets: cell surface targeting 
peptides (e.g. nisins and temporins) that including both 
membrane-targeting and non-membrane targeting 
peptides which can be further classified based on 
specific targets such as cell wall/carbohydrates, 
lipids/membranes, and proteins/receptors. Second 
family includes intracellular targeting peptides that can 
be further classified based on the specific target 
molecules (e.g. proteins (Pro-rich peptides), DNA, and 
RNA)11,12. 
Multidimensional properties of 
AMPs 
Beside antimicrobial activity, AMPs show other 
properties like biofilm control, antitumor property, 
mitogens activity and linking the innate immunity to 
the adaptive immunity. 
Antimicrobial activity 
AMPs have antimicrobial activity against bacteria, 
viruses, fungi and parasites with different mechanisms. 
NBM 71 Novelty in Biomedicine 2016, 2, 70-6 
Sadredinamin et al.                                                                                                   Antimicrobial Peptides (AMPs) 
AMPs with antibacterial 
activity 
AMPs show selective toxicity against bacteria 
comparing to eukaryotes. There are more negatively 
charged phospholipids in the membrane of bacteria 
compared to eukaryotic cells which composed of 
lipids without any net charges. These differences can 
lead to electrostatic interactions between cationic 
antimicrobial peptide and cytoplasmic membrane of 
bacteria. Some anionic peptides form a salt bridge 
through reaction of metal ions with negatively 
charged components of microbial membranes13,14. 
Unlike conventional antibiotics, peptide antibiotics 
target microbial cellular membranes which are 
different in various species of microorganisms from 
plants and animals. These important characteristics 
of peptide antibiotics effectively reduce the 
possibility of development of resistance against 
them8. 
Mechanisms of antibacterial 
activity 
AMPs perform antibacterial activity with the 
following method. 
Membrane disruption  
AMPs can form pore in the bacterial membrane with 
three mechanisms: 
Barrel-stave model: monomer peptides get 
aggregated on the surface and inserted into the cell 
membrane and form pore. This mechanism is well 
explained by analyzing a lantibiotic peptide nisin. 
Toroidal-pore model: peptide molecules are 
inserted into the membrane and inducing the lipid 
monolayers to continuously bend through the pore. 
For example melittin, LL-37 and MSI-78 can form 
pore with this mechanism. 
Carpet model: AMPs covering cell membranes of 
bacteria like a carpet, in threshold concentration 
reduce electrostatic force that causes membrane 
permeation and lysis of the microbial cell. For 
example magainins act by this mechanism4,15.  
Some AMPs influx into cell and inhibit cell wall, 
DNA, RNA, and protein synthesis16. 
Inhibition of cell wall synthesis 
Cell wall is a unique structure in bacterial cells that 
provides structural integrity. Because of the absence of 
cell wall structure in eukaryotic cells, prevention of 
cell wall synthesis is an attractive target for 
antibacterial peptides. In particular, lipid II which is an 
important precursor of peptidoglycan synthesis was 
shown to be an attractive target for antibacterial 
compounds. Several AMPs like Class I bacteriocins, 
nisin, Pep5, Mersacidin, Lcn972 and defensins can be 
target cell wall17. 
Inhibition of protein, RNA and 
DNA synthesis 
Some AMPs can penetrate into the cell without 
disrupting cell membrane and target intracellular 
components such as protein and acid nucleic synthesis. 
Some AMPs like buforin II binds to DNA and RNA 
which have been studied in Escherichiacolio rPR-39 
which can block DNA and protein synthesis and have 
multidimensional properties like wound repair, chemo 
attraction, angiogenesis, and inflammation17.  
AMPs with antiviral activity 
They can act in different ways including: blocking of 
viral receptors, inhibition of adsorption by binding of 
antimicrobial peptides to the viral proteins, interaction 
with co-receptors like CXCR4, inhibition of cell 
fusion by interfering of ATPase activity of protein, 
inhibition of gene expression, inhibition of peptide 
elongation and activation of an immune modulatory 
pathway2. 
AMPs with antifungal activity 
AMPs can target fungal cell membrane or their 
intracellular components like cell wall, DNA, RNA 
and proteins3. 
AMPs with anti-parasite activity 
Mechanism of antimicrobial peptides action is similar 
to others and they can disrupt cell membrane or target 
intracellular components like protein, RNA or DNA 
synthesis3. 
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Biofilm control 
Microorganisms can attach to the artificial implants 
surfaces and become resistant to environmental 
condition18. Antimicrobial peptides can be used as a 
therapeutic agent for biofilm control. Electrostatic 
interaction between antimicrobial peptides and cell 
surfaces could prevent biofilm formation. They can 
be effective in different ways for example preventing 
biofilm formation dose dependently like LL-37 
orcoating on implants surfaces to stop biofilm 
formation like Tet-20, histatin 5 and lactoferrin.  
In addition they can be used against drug resistant 
bacteria like nisin A and lacticin Q which can be 
effective against biofilm formation of a MRSA 
(Methicillin Resistant Staphylococcus aureus) strain. 
Some antimicrobial peptides can increase the 
sensitivity of ,l m. biofilm cells to other antibiotics 
like lactoferrin in which in combination with 
vancomycin can be used for the removing of S. 
epidermidis biofilms on contact lenses3. 
Antitumor activity 
Cancer is one of the most important reasons of 
morbidity and mortality throughout the world. In 
recent decades other therapies, such as 
chemotherapy, radiation, surgery, or hormone 
ablation are more used for cancer therapy but they 
are not successful in more than 50% of patients. 
Therefore there is an urgent need for new therapeutic 
agents. Several antimicrobial peptides have been 
studied as potential candidates for anticancer drugs. 
These molecules interact with different bilayers 
depending on the physical properties of membranes 
consisting of different lipid molecules. Their 
mechanism of action usually implicates the 
disruption of cancer cell membranes. These 
membranes are similar to membranes of bacterial cell 
with respect to their anionic characteristics. The 
cancer cell membrane has a negatively charged lipid 
phosphatidyl serine (PS) on their outer leaflet which 
differentiates them from normal cells that have a 
neutral charge due to the zwitterionic phosphatidyl 
choline and sphingomyelin. For example, LAH4 is 
an antimicrobial peptide that is shown to have both 
antibiotic and DNA delivery capabilities and it is a 
membrane-active peptide. The experimental studies 
indicate the greater tendency of LAH4 to interact with 
anionic membrane that can be useful data in order to 
confirm on its anticancer properties. Because of their 
different mechanism, resistance and cytotoxicity are 
less likely to arise for these peptides. Therefore AMPs 
are also expected to cause fewer side-effects than 
chemotherapeutic agents. As a result, AMPs are good 
candidates for development of new anticancer drugs 
and completing the usual anticancer therapy19.  
Also it is shown that anticancer peptides (ACPs) can 
kill cancer cells with other mechanism. Another 
mechanism of killing of cancer cells is the induction of 
mitochondrial pathway of apoptosis by either the 
cytochrome C release into the cytoplasm or the 
activation of the caspase cascade. Furthermore fluidity 
of cancer cells is greater than normal cells, which 
enhance the lytic activity of ACPs by enhancing the 
membrane destabilization. In addition because of the 
higher number of microvilli in the surface area of the 
tumorous cells membrane comparing non-tumorous 
cells, an increased number of peptides can bind to the 
surface area of the tumorous cells membrane2,20. 
Mitogens activity 
Mitogens properties of antimicrobial peptides was first 
introduced by Murphy et al. Defensins have several 
properties, one of these properties is ability to 
stimulated growth of fibroblasts and epithelial cells in 
vitro in concentration range required for antimicrobial 
activity. In other words, defensins can also induce a 
wound healing process besides preventing microbial 
infection21. A similar result was obtained by Aarbiou 
et al., for lung epithelial cells. In this study defensins 
enhanced proliferation of A549 lunge epithelial cells 
at 4–10 μg/ml by the MAP kinase path way and 
independent of the EGF-receptor22. Moreover another 
study suggested that human α-defensins have an 
effective role in the proliferation of both the normal 
and tumor cells in kidney. According to this study 
human α-defensins present in normal kidney and 
biopsies of renal carcinoma tissue. This study also 
showed that defensins were present at a concentration 
not exceeding 25g/ml stimulated DNA syntheses23. 
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Link innate to adaptive 
immunity 
Not only antimicrobial peptides have direct effect on 
bacterial membranes, but also are able to modulate 
other components of innate immunity. Gene 
expression of antimicrobial peptides has been 
controlled by immunity related transcription factors 
and by innate immunity cells including neutrophils, 
mast cells and eosinophils. So, they initiate signaling 
cascade of NAPDH oxidase-dependent mechanism 
that leads to the disintegration of the nuclear and 
cellular membrane24. For example, defensin also 
known as the regulator of innate immunity and 
secreted by a variety cells such as phagocytic cells 
and lymphocytes26. In the other hand, they can be 
effective as chemo attractants for monocytes and 
neutrophils. Moreover, defensins can produce several 
cytokines such as TNF and IL-1 in monocytes and 
induct IL-8 in lung epithelial cells24. As pretreatment 
of the cells with pertussis toxin, phospholipase C, 
phosphoinositide-3-kinase and Rho kinase inhibitors 
suppresses cell migration it is presumed that 
antimicrobial peptide-induced chemotaxis is 
mediated through G-protein-coupled receptors25. 
First study in 1996 by demonstrated that defenisns 
had chemotaxic activity in both nonspecific 




Despite of many advantage of AMPs which include 
broad-spectrum activity, rapid onset of activity, and 
relatively low possibility of resistance emergence, 
they still have some limitations for pharmaceutical 
development including; potential toxicity, conditions 
(susceptibility to proteases and extreme pH), lack of 
selectivity against specific strains, high produce cost 
and bacterial resistance27. Besides since AMPs have 
many similar features with eukaryotic nuclear 
localization signal peptides and because of their 
ability to translocate into cells, they can cause 
toxicities, including apoptosis, mast-cell 
degranulation or extracellular DNA transfer28. 
However it could be said that the main reason for 
unwilling of pharmaceutical industry in promoting the 
clinical use of these peptides as a class of antibacterial 
therapeutics is their high production cost. The 
synthesis of AMPs costs five to twenty times as high 
as that of conventional antibiotics28. The production of 
recombinant proteins in bacteria is by far the simplest 
and most inexpensive means to produce large amounts 
of peptide of interest8. On the other hand, after 
production of these peptides another problem for their 
pharmaceutical development is their stability.  
Protein and peptide stability is the result of a balance 
between the intramolecular interactions of protein 
functional groups and their interactions with the 
solvent environment. Addition of co-solvents into the 
protein solution can modify this balance29. The 
addition of co-solvents to solutions of peptides and 
proteins can result in a variety of effects such as 
denaturation, increased or decreased solubility, and 
secondary structure formation30. Protein transition 
from unfolded states to its native state is one of the 
most important biophysical processes. It is also of 
interest because of the important role it plays in the 
mechanisms and control of a lot of cellular processes. 
These include regulation of complex events during the 
cell cycle and translocation of proteins across 
biomembranes to their appropriate organelles31. 
Application of antimicrobial 
peptides 
Despite of restrictions mentioned about the use of 
antimicrobial peptides for therapeutic purposes, some 
of them are used as therapeutic agents32. For example 
they can be effective in combination with conventional 
antibiotics. Because of their synergic activity in 
association with other antibiotics, they have desirable 
effect in reducing the minimal inhibitory concentration 
(MIC) and minimal bactericidal concentrations (MBC) 
of those antibiotics. Several applications have been 
demonstrated for therapeutic application including: as 
single anti-infective agents, in combination with 
conventional antibiotics or antivirals to promote any 
additive or synergistic effects, as immune stimulatory 
agents that enhance natural innate immunity and as 
endotoxin neutralizing agents to prevent the 
potentially fatal complications associated with 
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bacterial virulence factors that cause septic shock33.  
In general, most of the researches about antimicrobial 
peptide devoted to tropical therapy due to the 
uncertainty about their long-term safety when 
administered systemically. On the other hand, in 
systematic studies it is shown that in spite of their 
activity in vitro, they can be effective in infection of 
animal models only at very high doses28. 
Below are some of AMPs that are used in drug 
development: 
1. Magainin is a 22-amino-acid linear 
antimicrobial peptide, isolated from the skin of 
the African clawed frog (Xenopuslaevis) which is 
in the phase 3 of clinical trial by companies 
Dipexium Pharma (White Plains, New 
York)/MacroChem/Genaera for Diabetic foot 
ulcers34. 
2. Omiganan a synthetic cationic peptide 
derived from indolicidin which is in the 
phase 2 of clinical trial by company BioWest 
Therapeutics/Maruho (Vancouver) for Rosacea34. 
3. NVB302 a Class B lantibiotic which is in the 
phase 1 of clinical trial by company Novacta 
(Welwyn Garden City, UK) for C. difficile 
infection34. 
4. Avidocin and purocin  a modified R-type 
bacteriocins from Pseudomonas aeruginosa which 
is in the preclinical by company Avid Biotics (S. 
San Francisco, California) and are narrow 
spectrum antibiotics for human health and food 
safety34. 
IMX924  a synthetic 5-amino-acid peptide 
innate defense regulator which is in the preclinical by 
company Iminex (Coquitlam, British Columbia, 
Canada) and is effective in Gram-negative and 
Gram-positive bacterial infections and improves 
survival and reduces tissue damage34. 
Conclusion 
AMPs are one of the important components of innate 
defense in a wide variety of organisms, from bacteria 
to humans. AMPs include a broad range of peptides 
with different chemical structures and conformations 
which all have certain properties in common. Their 
modes of action are very different and they 
demonstrate a great ability to exert a diverse range of 
antimicrobial effects. During recent years it has 
become evident that increasing bacterial drug 
resistance has created an urgent need for new classes 
of antibiotics. AMPs seem to represent promising 
properties for overcome this threat. On the other hand, 
AMPs have shown other potential and desirable 
therapeutic properties like antiviral, anticancer and 
contraceptive activities. Thus, understanding the 
diverse biological properties of AMPs can be very 
importance for clinical development of AMPs-based 
therapeutics. 
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